November 20, 2019 07:23 AM ESTUpdated 10:45 AM
Financing

Lon­don's bio­phar­ma-fo­cused GHO Cap­i­tal Part­ners claims close of largest-ever Eu­ro­pean fund

Natalie Grover

Reporter

Three years af­ter clos­ing out its first €660 mil­lion ($730.5 mil­lion) pri­vate eq­ui­ty fund, Lon­don-based GHO Cap­i­tal Part­ners has sealed a mam­moth $1 bil­lion-plus sec­ond …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

A service from the Financial Times